We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-4.61%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.5B
AUM Growth
-$546M
Cap. Flow
-$309M
Cap. Flow %
-6.85%
Top 10 Hldgs %
82.03%
Holding
109
New
17
Increased
29
Reduced
12
Closed
18

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$32.3M
2
BAC icon
Bank of America
BAC
+$19.3M
3
ARRY
Array Biopharma Inc
ARRY
+$16.6M
4
MS icon
Morgan Stanley
MS
+$13.2M
5
APTV icon
Aptiv
APTV
+$10.7M

Sector Composition

Rank Sector Weight
1 Consumer Staples 46.77%
2 Healthcare 25.98%
3 Consumer Discretionary 7.97%
4 Financials 0.43%
5 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TCOM icon
101
Trip.com Group
TCOM
$29.3B
-100,000
Closed -$4.66M
TSLA icon
102
Tesla
TSLA
$1.21T
-750,000
Closed -$10.2M
USFD icon
103
US Foods
USFD
$22.7B
-225,000
Closed -$5.31M
VVV icon
104
Valvoline
VVV
$5.1B
-150,000
Closed -$3.52M
ISEE
105
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
-30,000
Closed -$1.38M
AMAG
106
DELISTED
AMAG Pharmaceuticals
AMAG
-300,000
Closed -$7.35M
SPNC
107
DELISTED
Spectranetics Corp
SPNC
-200,000
Closed -$5.02M
AEGR
108
DELISTED
Aegerion Pharmaceuticals
AEGR
-1,000,000
Closed -$2.97M
DO
109
DELISTED
Diamond Offshore Drilling
DO
-100,000
Closed -$1.76M

Similar funds

Artal Group's Q4 2016 Portfolio in Review

As of Q4 2016, Artal Group held 109 positions worth $4.5B, down 11% from $5.05B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Artal Group withdrew a net $309M in Q4 2016, closing 18 positions and reducing 12 holdings. Its most notable exit was Goldman Sachs, an estimated $32.3M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 47% of assets, up from 41% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Alexion Pharmaceuticals worth $24.5M.

  • Artal Group's largest Q4 2016 buy was Alexion Pharmaceuticals: 200,000 shares worth $24.5M.
  • Artal Group added most to Agios Pharmaceuticals in Q4 2016, an estimated $18.4M increase.
  • Artal Group's biggest Q4 2016 reduction was Array Biopharma Inc, cutting an estimated $16.6M.
  • Artal Group fully exited Goldman Sachs in Q4 2016, selling an estimated $32.3M.
  • Artal Group's ten largest holdings make up 82% of its $4.5B portfolio in Q4 2016.
  • Artal Group opened 17 new positions and closed 18 in Q4 2016.
  • Artal Group's portfolio value fell 11% quarter-over-quarter to $4.5B.

Based on Artal Group's 13F filing for Q4 2016, filed 14 Feb 2017.